<DOC>
	<DOCNO>NCT00567086</DOCNO>
	<brief_summary>To evaluate effect single sc administration TEZAMPANEL one three different dosage level compare placebo , employ traditional measure efficacy safety treatment single episode acute migraine .</brief_summary>
	<brief_title>Study Assess Safety , Tolerance Efficacy Tezampanel Patients With Acute Migraine</brief_title>
	<detailed_description>Primary : • Headache relief ( headache response ) define percentage patient treatment group experience decrease pain moderate severe intensity pre-dose ( baseline ) mild pain 2 hour study drug administration prior use rescue medication . Secondary : - Percentage patient treatment group pain-free two hour study drug administration , prior use rescue medication - Sustained headache response rate ( percentage patient treatment group headache response Hour 2 rescue medication headache recurrence 2 24 hour ) - Sustained pain-free rate ( percentage patient treatment group pain free Hour 2 rescue medication headache recurrence 2 48 hour ) - Recurrence rate ( percentage patient treatment group Hour 2 mild response pain-free response subsequently develop headache rat moderate severe intensity within 2 24 hour ) - Relapse rate ( percentage patient treatment group Hour 2 pain free response subsequently develop headache rat moderate severe intensity within 2 48 hour</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Patients meet follow inclusion criterion screen consider admission study : 1 . Males female age 18 65 year , inclusive . . Females childbearing potential must risk pregnancy study . 2 . Patients must meet IHS diagnostic criterion migraine , without aura . 3 . Patients history 1 6 acute migraine headache attack per month 1 migraine headache within past 30 day . 4 . Patients least 1year history migraine headache . 5 . Patients ≤ 50 year age initial migraine onset . 6 . Patients must able distinguish migraine headache discreet headache headache , tensiontype headache . Additionally , patient experience least 48 hour freedom headache migraine attack . 7 . Patients must complete medical history ( include headache history ) , ECG , PE screen include formal assessment visual acuity ( Snellen chart ) visual field integrity visit . 8 . Patients must able comprehend satisfactorily comply protocol requirement , opinion investigator . Patients meet follow exclusion criterion screen eligible participation study . 1 . Patients also suffer concomitant frequent , nonmigraine headache ≥6 days/month suffer frequent migraine define average &gt; 6 attack per month . 2 . Patients fail present migraine attack treatment within 30 day screen . 3 . Patients menstrual migraine : migraine attack occur day 2 +3 ( Day 1 first day menstruation ) menses occur rest month . 4 . Patients clinically significant active unstable systemic , renal , hepatic , gastrointestinal , neurological , endocrine , metabolic , psychiatric disease determine medical history physical examination . Patients breastfeed exclude . Patients history cardiovascular illness , ischemic stroke , ischemic heart disease , Prinzmetal 's angina , hypertension exclude . 5 . Patients receive experimental drug within one month prior one month subsequent screening . 6 . Patients take MAOI within 14 day prior randomization 7 . Patients allergic show hypersensitivity compound similar pharmacology TEZAMPANEL . 8 . Patients meet DSMIVTR criterion significant psychoactive substance use disorder ( abuse , dependence , and/or withdrawal ) within past 90 day . 9 . Patients clinically significant abnormal laboratory test result screen . 10 . Patients clinically notable vital sign abnormality screen . 11 . Patients exclude 2 consecutive urine drug screening positive . 12 . Patients exclude evidence visual field disturbance . 13 . Patients participate previous TEZAMPANEL ( NGX424 LY293558 ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Migraine</keyword>
</DOC>